ARGX-213 — Competitive Intelligence Brief

ARGX-213 (ARGX-213) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody. Area: Immunology.

phase 1 Monoclonal antibody CD20 Immunology Biologic

Target snapshot

ARGX-213 (ARGX-213) — argenx. Monoclonal antibody targeting CD20

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ARGX-213 TARGET	ARGX-213	argenx	phase 1	Monoclonal antibody	CD20
Venetoclax; Rituximab	venetoclax-rituximab	Pfizer	marketed	BCL-2 inhibitor (venetoclax); Monoclonal antibody (rituximab)	BCL-2 (venetoclax); CD20 (rituximab)	N/A
Columvi	glofitamab	Roche	marketed	Bispecific CD20-directed CD3 T Cell Engager [EPC]	B-lymphocyte antigen CD20	2023-01-01
Lunsumio	MOSUNETUZUMAB	Roche	marketed		B-lymphocyte antigen CD20	2022-01-01
Ocrevus	OCRELIZUMAB	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2017-01-01
Gazyva	obinutuzumab	Roche	marketed	CD20-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD20	2013-01-01
Kesimpta	OFATUMUMAB	Novartis	marketed	Anti-CD20 monoclonal antibody	CD20	2009-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody class)

1. Pfizer · 7 drugs in this class
2. argenx · 7 drugs in this class
3. Johnson & Johnson · 2 drugs in this class
4. German CLL Study Group · 2 drugs in this class
5. Amgen · 2 drugs in this class
6. Hoffmann-La Roche · 2 drugs in this class
7. Brii Biosciences Limited · 2 drugs in this class
8. Alexion Pharmaceuticals, Inc. · 2 drugs in this class
9. Biotest · 2 drugs in this class
10. Fondazione Italiana Linfomi - ETS · 2 drugs in this class